Oramed Pharmaceuticals Issues Letter to Shareholders
Oramed Pharmaceuticals Inc. (ORMP)
Last oramed pharmaceuticals inc. earnings: 4/6 04:46 pm
Check Earnings Report
US:NASDAQ Investor Relations:
oramed.com/investors
Company Research
Source: PR Newswire
NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter to shareholders from Chief Executive Officer Nadav Kidron. For a video message from Mr. Kidron click here. Dear Shareholders,2019 was a great year of progress for Oramed. We are excited to report that the U.S. Food and Drug Administration (FDA) has agreed to an End of Phase 2 Chemistry Manufacturing and Control (CMC) meeting on February 4, 2020. We expect additional meetings with both the FDA and the European Medicines Agency (EMA), during which we anticipate receiving the regulatory agencies' guidance on our Phase 3 study design. We believe this milestone is the culmination of the hard work and dedication of our employees and investors, and positions us closer to achieving our goal of developing the world's first oral insulin capsule
Show less
Read more
Impact Snapshot
Event Time:
ORMP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORMP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORMP alerts
High impacting Oramed Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ORMP
News
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
ORMP
Earnings
- 8/14/24 - Beat
ORMP
Sec Filings
- 12/17/24 - Form 8-K
- 11/8/24 - Form 4
- 11/8/24 - Form 4
- ORMP's page on the SEC website